Clinical Trials Logo

Advanced Solid Malignancies clinical trials

View clinical trials related to Advanced Solid Malignancies.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06028074 Recruiting - Clinical trials for Advanced Solid Malignancies

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

Start date: December 12, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.

NCT ID: NCT05417594 Recruiting - Clinical trials for Advanced Solid Malignancies

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

CERTIS1
Start date: June 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in 490 participants with advanced cancer that has recurred/progressed.

NCT ID: NCT05315167 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Start date: May 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open-label study to assess the safety and preliminary efficacy and to determine the maximum tolerated dose (MTD) or maximum administration dose (MAD) and recommended Phase 2 doses (RP2D) of PRJ1-3024 in subjects with relapsed/refractory solid tumors. The study consists of two parts, one is a 3+3 dose escalation study and another is a pharmaceutical extension of RP2D.

NCT ID: NCT05159700 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Start date: March 31, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase I, multicenter, open-label, 3+3 dose escalation study to determine the safety and preliminary efficacy of PRJ1-3024 in subjects with relapsed/refractory solid tumors.

NCT ID: NCT04521413 Recruiting - Clinical trials for Advanced Solid Malignancies

Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies

Start date: August 31, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.

NCT ID: NCT04136834 Recruiting - Clinical trials for Advanced Solid Malignancies

A Phase I Open-label Study for Subjects With Advanced Malignancies

PT01
Start date: April 21, 2021
Phase: Phase 1
Study type: Interventional

This is a first-in-human (FIH) Phase 1 dose escalation study to evaluate the safety, tolerability, PK, PD, and preliminary activity of PT01 administered IV in subjects with advanced malignancies.'

NCT ID: NCT02347228 Recruiting - Clinical trials for Advanced Solid Malignancies

Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies

Start date: September 11, 2020
Phase: Phase 1
Study type: Interventional

The objectives of this Phase I study are to determine the maximum tolerable dose (MTD) and to evaluate pharmacokinetics (PK), safety/ tolerability and preliminary efficacy of OB318 in patients with advanced solid malignancies.

NCT ID: NCT01024283 Recruiting - Clinical trials for Advanced Solid Malignancies

Analysis of Pharmacodynamic Changes With AUY922A, an HSP90 Inhibitor

Start date: December 2008
Phase: Phase 1/Phase 2
Study type: Observational

The principal research objective of this additional research protocol is to support the collection, storage and use of tumour and surrogate (peripheral blood mononuclear cells - PBMNCs). The objective of this study is to perform assays to study pharmacodynamic (PD) markers that confirm target modulation.